<DOC>
	<DOCNO>NCT01943292</DOCNO>
	<brief_summary>This phase I , open-label , dose-escalation trial defactinib ( VS-6063 ) , focal adhesion kinase inhibitor , Japanese patient non-hematologic malignancy . The purpose study assess safety ( include recommend phase 2 dose ) , pharmacokinetics , anti-cancer activity defactinib ( VS-6063 ) .</brief_summary>
	<brief_title>Phase I Dose Escalation Study VS-6063 Japanese Subjects With Non-Hematologic Malignancies</brief_title>
	<detailed_description />
	<criteria>Able provide sign date informed consent prior initiation study procedure . Age ≥ 20 year . Subject must Japanese descent . Subjects must histopathologically confirm diagnosis nonhematologic malignancy . Subjects must standard care option refuse standard therapy . All persistent clinically significant toxicity prior chemotherapy must ≤ Grade 1 . ECOG performance status 0 1 , measure within 72 hour start treatment . Predicted life expectancy ≥ 3 month . Adequate renal function [ creatinine ≤ 1.5x ULN ( upper limit normal ) ] GFR ≥ 50mL/min . Adequate hepatic function ( total bilirubin ≤ 1.5x ULN institution ; AST [ aspartate transaminase ] ALT [ alanine transaminase ] ≤ 3x ULN , ≤ 5x ULN due liver involvement tumor ) . Adequate bone marrow function ( hemoglobin ≥ 9.0 g/dL ; platelet ≥ 100 x109 cells/L ; absolute neutrophil count ≥ 1.5x109 cells/L ) . Corrected QT interval ( QTc ) &lt; 470 m ( calculate Fridericia correction formula ) . Negative pregnancy test woman childbearing potential . ( A woman childbearing potential define one biologically capable become pregnant except woman undergone permanent contraceptive surgery postmenopausal ( define absence menstruation least 12 month without medical reason ) . Men woman child bear potential must agree use adequate birth control throughout participation study 90 day follow last study treatment . Willing able participate trial comply trial requirement . Gastrointestinal ( GI ) condition could interfere swallow absorption study medication . Uncontrolled severe concurrent medical condition ( include uncontrolled brain metastasis ) . Stable brain metastasis either treat treat stable dose steroids/ anticonvulsant , dose change within 28 day prior first dose study drug , allow . History upper gastrointestinal bleeding , ulceration , perforation within 12 month prior first dose study drug . Known history stroke cerebrovascular accident within 6 month prior first dose study drug . Subjects know infection human immunodeficiency virus ( HIV ) Acquired Immune Deficiency Syndrome ( AIDS ) ( test require ) . Subjects know Hepatitis B C ( Including know seropositivity Hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV antibody ) . Subjects actively treat secondary malignancy . Cancerdirected therapy ( chemotherapy , radiotherapy , hormonal therapy , biologic immunotherapy , etc . ) within 28 day first dose study drug 5 halflives , whichever short . Major surgery within 28 day prior first dose study drug . Use investigational drug within 28 day 5 halflives ( whichever short ) prior first dose study drug . A minimum 10 day termination investigational drug administration study treatment require . In addition , drugrelated toxicity except alopecia recover grade 1 less . Women pregnant breastfeeding . Any evidence serious active infection . Uncontrolled severe cardiovascular disease , include myocardial infarct unstable angina within 6 month prior study treatment , New York Heart Association ( NYHA ) Class II great congestive heart failure , serious arrhythmia require medication treatment , clinically significant pericardial disease , cardiac amyloidosis . Known history malignant hypertension Uncontrolled intercurrent illness include symptomatic congestive heart failure , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Focal Adhesion Kinase inhibitor</keyword>
	<keyword>FAK inhibitor</keyword>
	<keyword>Cancer Stem Cells</keyword>
	<keyword>CSC</keyword>
</DOC>